NSE: TORNTPHARM | BSE: 500420

Expensive Performer

Download real time

3629.20 61.80 (1.73%)

Near 52W High of ₹3787.90

316.7K NSE+BSE Volume

NSE 19 Sep, 2025 3:53 PM (IST)

122,828.6

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Torrent Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for TORNTPHARM, BSE:500420 Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

03 Aug 2021

3629.20

1.73%

TORRENT PHARMA

Buy: Torrent Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. The company...

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

28 Jul 2021

3629.20

1.73%

DF on a strong footing; making inroads in Trade Generics

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

TRP's 1QFY22 performance was largely in line with our estimates. Growth momentum in the Domestic Formulation (DF) business was offset by a muted showing in the US business and a higher tax rate. It continues to...

Torrent Pharmaceutic.. has an average target of 3746.00 from 5 brokers.

Torrent Pharmaceuticals Ltd.

28 Jul 2021

3629.20

1.73%

Torrent Pharmaceuticals

Hold: Torrent Pharmaceuticals Ltd.

Recommendation Target

ICICI Securities Limited

A strong growth track in top brands, measured new launches (including innovative launches) besides strong balance sheet and comfort on corporate governance front are some key attributes of Sanofi...

Torrent Pharmaceuticals Ltd. is trading above all available SMAs

Torrent Pharmaceuticals Ltd.

19 May 2021, 12:00AM

3629.20

1.73%

Steady outperformance in the Branded Generics segment

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

TRP's 4QFY21 result was marginally below our estimates at an operational level, led by a sharp YoY decline in US and CRAMS sales. It continues to build its product portfolio and enhance marketing efforts to outperform in Brazil, Germany, and the Branded Generics segment in Domestic Formulation (DF)....

Torrent Pharmaceuticals Ltd.'s price crossed above 30Day SMA today

Torrent Pharmaceuticals Ltd.

19 May 2021, 12:00AM

3629.20

1.73%

Torrent Pharmaceuticals

Buy: Torrent Pharmaceuticals Ltd.

ICICI Securities Limited

Q4 operational performance was in line with I-direct estimates whereas bottomline was better amid higher-than-expected other income and lower interest cost. Overhang pertaining to two US focused plants notwithstanding, Torrent continues to impress thanks to its robust margin profile that can be attributed to global portfolio that comprises ~60% branded generics. We expect a further improvement in this matrix, product rationalisation to further strengthen margins. The company's portfolio is finely balanced between India, Brazil, Germany and the US with India being...

Torrent Pharmaceuticals Ltd.'s price crossed above 50Day SMA today

Torrent Pharmaceuticals Ltd.

11 Feb 2021

3629.20

1.73%

TORRENT PHARMA

Buy: Torrent Pharmaceuticals Ltd.

Target

Geojit BNP Paribas

Torrent Pharmaceuticals Ltd.'s price crossed above 30Day SMA today

Torrent Pharmaceuticals Ltd.

09 Feb 2021

3629.20

1.73%

Torrent Pharmaceuticals

Buy: Torrent Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Q3 results were mostly in line with I-direct estimates (albeit skewed) on all fronts. While growth in India and Germany was mostly offset by decline in the US and Brazil, overall profitability was higher YoY amid lower on-ground activities and a lower tax rate. Overhang pertaining to two US focused plants notwithstanding, Torrent continues to impress thanks to its robust margin profile that can be attributed to global portfolio that comprises ~65% branded generics. We expect a further improvement in this matrix, product rationalisation to further strengthen margins. The company's portfolio is...

Torrent Pharmaceutic.. has an average target of 3746.00 from 5 brokers.

Torrent Pharmaceuticals Ltd.

08 Feb 2021

3629.20

1.73%

DF, Germany, controlled cost drive earnings

Neutral: Torrent Pharmaceuticals Ltd.

Target

Motilal Oswal

Torrent Pharma (TRP)'s 3QFY21 performance was below estimates. Recovery in the Domestic Formulation (DF) / Germany business was offset by decline in the US and currency headwinds in Brazil. Reduced opex kept profitability at elevated levels. We reduce our EPS estimates for FY21/FY22/FY23 by 4%/8%/6%, factoring in a) an increase in operational expenses with the resumption of promotional activity by MRs in the DF segment and b) the lack of new approvals due to USFDA-imposed regulatory issues at Dahej/Indrad. We continue to value...

Torrent Pharmaceutic.. has an average target of 3746.00 from 5 brokers.

Torrent Pharmaceuticals Ltd.

04 Nov 2020

3629.20

1.73%

Torrent Pharma's FY20 Annual Report analysis highlights modest revenue growth of 3.5 %

Strategy Note: Torrent Pharmaceuticals Ltd.

Motilal Oswal

Torrent Pharma's FY20 Annual Report analysis highlights modest revenue growth of 3.5%, led by decline in the US (4.2%) and Germany (6.1%). However, businesses in India/ROW registered growth of 8.8%/12.8%. EBITDA margins expanded 150bp to 27.3% due to higher gross margins, lower R&D; spends (at 6.2% of revenue v/s 7.0% in FY19), containment of employee expenses (at 18.0% of revenues v/s 18.3% in FY19) with reduced manpower (by 750 people), and capitalization of part employee expenses during upgradation of the Levittown facility. PAT excluding...